×
About 960 results

ALLMedicine™ Oncology Treatment Center

Research & Reviews  237 results

Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment...
https://doi.org/10.1007/s11060-023-04285-8
Journal of Neuro-oncology; Bleeker L, Kouwenhoven MCM et. al.

Mar 16th, 2023 - Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients. Adult medulloblastoma patients diagnosed b...

Unmet Needs and Receipt of Supportive Care Services in Head and Neck Cancer Patients Pr...
https://doi.org/10.1177/00034894231154182
The Annals of Otology, Rhinology, and Laryngology; Day AT, Prestwood CA et. al.

Mar 10th, 2023 - To characterize the supportive care (SC) needs and receipt of SC services among head and neck cancer (HNC) patients prior to oncologic treatment and to explore the influence of social determinants of health on these outcomes. Newly diagnosed HNC p...

A clinical phase I dose-finding design with adaptive shrinking boundaries for drug comb...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979534
BMC Medical Research Methodology; Li Z, Xu Z et. al.

Mar 3rd, 2023 - Combinations of drugs are becoming increasingly common in oncology treatment. In some cases, patients can benefit from the interaction between two drugs, although there is usually a higher risk of developing toxicity. Due to drug-drug interactions...

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
https://clinicaltrials.gov/ct2/show/NCT05585684

Mar 2nd, 2023 - Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Sec...

AIMS Cancer Outcomes Study
https://clinicaltrials.gov/ct2/show/NCT04495790

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

see more →

Guidelines  1 results

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and ...
https://doi.org/10.1016/j.kint.2020.06.046
Kidney International; Porta C, Bamias A et. al.

Nov 1st, 2020 - The association between kidney disease and cancer is multifaceted and complex. Persons with chronic kidney disease (CKD) have an increased incidence of cancer, and both cancer and cancer treatments can cause impaired kidney function. Renal issues ...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  30 results

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
https://clinicaltrials.gov/ct2/show/NCT05585684

Mar 2nd, 2023 - Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Sec...

AIMS Cancer Outcomes Study
https://clinicaltrials.gov/ct2/show/NCT04495790

Feb 1st, 2023 - It is estimated that between 50 and 80% of cancer patients in the United States (US) supplement their conventional medical treatment regimen with some form of complementary or alternative medicine (CAM) therapy or practice. A smaller percentage of...

MIRA Clinical Learning Environment (MIRACLE): Lung
https://clinicaltrials.gov/ct2/show/NCT05689437

Jan 19th, 2023 - Novel data science and imaging-based methods to personalize care are being identified retrospectively and explored at many centers. Unfortunately, most of these methods require significant manual intervention to apply to any given patient situatio...

Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03677076

Dec 7th, 2022 - This study proposes to document the presence of clonal emergence and regression during radium-223 therapy for metastatic prostate cancer by serial ctDNA analysis of tumor-associated mutations, using the clinically-available Guardant 360 platform. ...

Evaluation of the French Translation of Gothenburg Trismus Questionnaire (GTQ)
https://clinicaltrials.gov/ct2/show/NCT05615181

Nov 18th, 2022 - Trismus is defined as a limitation in the mouth/jaw-opening ability due to a reduced mandible mobility. Trismus can occur from benign jaw related conditions, often referred to as temporomandibular disorders (TMD). It can also result from local or ...

see more →

News  114 results

Assay Offers Molecular Analysis of Breast Cancer Risk Recurrence: Interview With Kenneth J. Bloom, MD
https://www.onclive.com/view/assay-offers-molecular-analysis-of-breast-cancer-risk-recurrence-an-interview-with-kenneth-j-bloom-md

Mar 10th, 2022 - Kenneth J. Bloom, MD Chief Medical Of ficer Clarient, Inc The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment, particularly in br...

Trop-2 Directed Antibody-Drug Conjugates for the Treatment of Solid Tumors
https://www.onclive.com/view/trop-2-directed-antibody-drug-conjugates-for-the-treatment-of-solid-tumors

Mar 1st, 2022 - The oncology treatment landscape has evolved with the clinical development of precision-based therapeutic approaches and the growing availability of targeted agents.1,2 Over the last decade, targeted therapeutics have increasingly become an attrac...

Relapsed/Refractory Follicular Lymphoma Has a Bounty of Options in the Third Line
https://www.onclive.com/view/relapsed-refractory-follicular-lymphoma-has-a-bounty-of-options-in-the-third-line

Feb 24th, 2022 - Slow disease progression is often associated with low-grade follicular lymphoma. Despite the use of watch-and-wait approaches for the disease in early, low-grade stages, patients may eventually require treatment. Patients live with this disease fo...

Checkpoint Inhibitor Changes Take Hold: Approval Standards Stir Debate
https://www.onclive.com/view/checkpoint-inhibitor-changes-take-hold-approval-standards-stir-debate

Feb 16th, 2022 - After 7 years of explosive growth, the development of PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy underwent a course correction last year, with the withdrawal of a range of indications due to study results that failed to reach thresholds ...

American Oncology Network Appoints New Vice President of Business Development
https://www.onclive.com/view/american-oncology-network-appoints-new-vice-president-of-business-development

Nov 17th, 2021 - American Oncology Network, LLC (AON), a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in community-based settings, announced that John Misitis has joined as Vice President of Busines...

see more →